长期使用白细胞介素-1抑制剂可减少进行性骨化性纤维发育不良患者的急性发作活动
本文报告了4例进行性骨化性纤维发育不良(FOP)患者接受抗白细胞介素-1(IL-1)治疗的短期和长期反应,所有患者在治疗期间急性发作活动持续改善,新发异位骨化部位极少;2例停药后发作复发,重新用药后再次被抑制。儿童健康评估问卷证实疼痛和总体健康视觉模拟量表有广泛主观改善。
要点
- 4例FOP患者接受IL-1抑制剂治疗后急性发作活动持续改善,新发异位骨化部位极少。
- 2例停药后发作活动复发,重新用药后再次被抑制。
- 儿童健康评估问卷证实疼痛和总体健康视觉模拟量表有广泛主观改善。
核心结论
- 本病例系列表明IL-1抑制剂在减少FOP患者急性发作活动和改善总体健康方面有显著获益。
- 这些数据为开展更多研究以更好理解IL-1抑制的作用(主要是在减少新发异位骨化形成方面)提供了有力支持。
研究设计与样本
- 病例系列,报告1例既往已报道的FOP患者长期接受IL-1抑制剂治疗的结果,并描述来自两个医疗中心的另外3例患者。
主要发现
- 全部4例患者在IL-1抑制剂治疗期间急性发作活动持续改善,新发异位骨化部位极少。
- 2例停止治疗的患者出现急性发作活动复发,重新开始治疗后再次被抑制。
- 这些患者的IL-1β水平与IL-1β驱动性疾病中的水平相当。
- 儿童健康评估问卷证实疼痛和总体健康视觉模拟量表有广泛主观改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Fibrodysplasia ossificans progressiva (FOP) is one of the most catastrophic forms of genetic heterotopic ossification (HO). FOP is characterized by severe, progressive inflammatory flare-ups, that often lead to HO. The flare-ups are associated with increased inflammatory cytokine production, suggesting auto-inflammatory features driven by IL-1β. This study describes the short- and long-term responses of FOP patients to anti-IL-1 therapy. METHODS: Previously, we reported that a patient with FOP treated with anti-IL-1 agents showed dramatically lower rates of flare-ups, improved flare-up symptoms, decreased use of glucocorticoids and apparently decreased size of residual lesions. Plasma analyses also showed marked elevation in IL-1β levels during a FOP flare, further supporting a role of IL-1β in the pathogenesis of FOP flares. Here, we report results from long-term therapy with IL-1 inhibitors in that patient and describe 3 additional patients, from two medical centres. RESULTS: All 4 patients showed persistent improvement in flare activity during treatment with IL-1 inhibitors, with minimal formation of new HO sites. Two patients who stopped therapy experienced a resurgence of flare activity that was re-suppressed upon re-initiation. These patients had IL-1β levels comparable to those in IL-1β-driven diseases. Child Health Assessment Questionnaires confirmed extensive subjective improvements in the pain and general health visual analogue scales. CONCLUSION: This case series demonstrates significant benefits from IL-1 inhibitors for reducing flare activity and improving the general health of patients with FOP. These data provide strong support for additional studies to better understand the function of IL-1 inhibition, primarily in reducing the formation of new HO. FUNDING: RH received support from the International FOP Association ACT grant; ECH received support from NIH/NIAMS R01AR073015 and the UCSF Robert Kroc Chair in Connective Tissue and Rheumatic Diseases III.
引用
- Haviv R, Zeitlin L, Moshe V, et al. Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva. Rheumatology (Oxford). 2024. PMID: 38733591. doi:10.1093/rheumatology/keae255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。